Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.44
MDVN's Cash to Debt is ranked lower than
70% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. MDVN: 2.44 )
Ranked among companies with meaningful Cash to Debt only.
MDVN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 10000.00 Max: No Debt
Current: 2.44
Equity to Asset 0.61
MDVN's Equity to Asset is ranked lower than
60% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MDVN: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
MDVN' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.49 Max: 0.99
Current: 0.61
0.01
0.99
Interest Coverage 35.25
MDVN's Interest Coverage is ranked lower than
71% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MDVN: 35.25 )
Ranked among companies with meaningful Interest Coverage only.
MDVN' s Interest Coverage Range Over the Past 10 Years
Min: 12.99  Med: 10000.00 Max: 9999.99
Current: 35.25
12.99
9999.99
F-Score: 4
Z-Score: 12.25
M-Score: -0.43
WACC vs ROIC
9.58%
85.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 43.96
MDVN's Operating margin (%) is ranked higher than
95% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. MDVN: 43.96 )
Ranked among companies with meaningful Operating margin (%) only.
MDVN' s Operating margin (%) Range Over the Past 10 Years
Min: -510.27  Med: -33.39 Max: 43.96
Current: 43.96
-510.27
43.96
Net-margin (%) 25.94
MDVN's Net-margin (%) is ranked higher than
90% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. MDVN: 25.94 )
Ranked among companies with meaningful Net-margin (%) only.
MDVN' s Net-margin (%) Range Over the Past 10 Years
Min: -496.58  Med: -38.58 Max: 38.91
Current: 25.94
-496.58
38.91
ROE (%) 40.89
MDVN's ROE (%) is ranked higher than
97% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. MDVN: 40.89 )
Ranked among companies with meaningful ROE (%) only.
MDVN' s ROE (%) Range Over the Past 10 Years
Min: -862.65  Med: -91.55 Max: 105.07
Current: 40.89
-862.65
105.07
ROA (%) 23.44
MDVN's ROA (%) is ranked higher than
97% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. MDVN: 23.44 )
Ranked among companies with meaningful ROA (%) only.
MDVN' s ROA (%) Range Over the Past 10 Years
Min: -68.11  Med: -16.91 Max: 42.39
Current: 23.44
-68.11
42.39
ROC (Joel Greenblatt) (%) 223.08
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. MDVN: 223.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDVN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -201825  Med: -4226.22 Max: 299.97
Current: 223.08
-201825
299.97
Revenue Growth (3Y)(%) 65.20
MDVN's Revenue Growth (3Y)(%) is ranked higher than
90% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. MDVN: 65.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDVN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 113.1
Current: 65.2
0
113.1
» MDVN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

MDVN Guru Trades in Q2 2015

Steven Cohen 98,700 sh (New)
Jim Simons 795,100 sh (+83.11%)
Joel Greenblatt 250,394 sh (+66.35%)
Ken Fisher 2,400 sh (unchged)
Louis Moore Bacon Sold Out
» More
Q3 2015

MDVN Guru Trades in Q3 2015

Paul Tudor Jones 12,934 sh (New)
Steven Cohen 1,641,334 sh (+1562.95%)
Ken Fisher 6,300 sh (+162.50%)
Joel Greenblatt Sold Out
Jim Simons 694,700 sh (-12.63%)
» More
Q4 2015

MDVN Guru Trades in Q4 2015

Pioneer Investments 149,693 sh (New)
Paul Tudor Jones 127,060 sh (+882.37%)
Steven Cohen 2,002,700 sh (+22.02%)
Ken Fisher 6,615 sh (+5.00%)
Jim Simons Sold Out
» More
Q1 2016

MDVN Guru Trades in Q1 2016

Ken Fisher 6,631 sh (+0.24%)
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Medivation Inc

Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Top insiders make large sales of stock
According to GuruFocus Insider Data, the largest insider sells during the past week were: Medivation Inc. (NASDAQ:MDVN), JPMorgan Chase & Co. (NYSE:JPM), Stryker Corporation (NYSE:SYK) and Sabre Corp. (NASDAQ:SABR). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 42.88
MDVN's P/E(ttm) is ranked lower than
60% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. MDVN: 42.88 )
Ranked among companies with meaningful P/E(ttm) only.
MDVN' s P/E(ttm) Range Over the Past 10 Years
Min: 20.81  Med: 34.98 Max: 330.65
Current: 42.88
20.81
330.65
Forward P/E 27.78
MDVN's Forward P/E is ranked lower than
76% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. MDVN: 27.78 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 43.19
MDVN's PE(NRI) is ranked lower than
59% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. MDVN: 43.19 )
Ranked among companies with meaningful PE(NRI) only.
MDVN' s PE(NRI) Range Over the Past 10 Years
Min: 20.96  Med: 35.06 Max: 325.93
Current: 43.19
20.96
325.93
Price/Owner Earnings (ttm) 38.22
MDVN's Price/Owner Earnings (ttm) is ranked higher than
50% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. MDVN: 38.22 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDVN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.15  Med: 30.96 Max: 1560.71
Current: 38.22
3.15
1560.71
P/B 11.29
MDVN's P/B is ranked lower than
84% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. MDVN: 11.29 )
Ranked among companies with meaningful P/B only.
MDVN' s P/B Range Over the Past 10 Years
Min: 4.74  Med: 35.60 Max: 2053.33
Current: 11.29
4.74
2053.33
P/S 10.60
MDVN's P/S is ranked higher than
52% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. MDVN: 10.60 )
Ranked among companies with meaningful P/S only.
MDVN' s P/S Range Over the Past 10 Years
Min: 4.43  Med: 21.88 Max: 650
Current: 10.6
4.43
650
PFCF 49.47
MDVN's PFCF is ranked lower than
65% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. MDVN: 49.47 )
Ranked among companies with meaningful PFCF only.
MDVN' s PFCF Range Over the Past 10 Years
Min: 2.96  Med: 35.72 Max: 260.74
Current: 49.47
2.96
260.74
POCF 45.15
MDVN's POCF is ranked lower than
68% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. MDVN: 45.15 )
Ranked among companies with meaningful POCF only.
MDVN' s POCF Range Over the Past 10 Years
Min: 2.96  Med: 32.97 Max: 206.47
Current: 45.15
2.96
206.47
EV-to-EBIT 24.69
MDVN's EV-to-EBIT is ranked higher than
51% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. MDVN: 24.69 )
Ranked among companies with meaningful EV-to-EBIT only.
MDVN' s EV-to-EBIT Range Over the Past 10 Years
Min: -650.3  Med: -24.55 Max: 157.5
Current: 24.69
-650.3
157.5
EV-to-EBITDA 24.41
MDVN's EV-to-EBITDA is ranked lower than
55% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. MDVN: 24.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDVN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1185.6  Med: -24.85 Max: 144.7
Current: 24.41
-1185.6
144.7
Shiller P/E 1886.27
MDVN's Shiller P/E is ranked lower than
100% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. MDVN: 1886.27 )
Ranked among companies with meaningful Shiller P/E only.
MDVN' s Shiller P/E Range Over the Past 10 Years
Min: 971.33  Med: 1355.34 Max: 1926.67
Current: 1886.27
971.33
1926.67
Current Ratio 2.38
MDVN's Current Ratio is ranked lower than
71% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. MDVN: 2.38 )
Ranked among companies with meaningful Current Ratio only.
MDVN' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 3.88 Max: 27.3
Current: 2.38
1.88
27.3
Quick Ratio 2.38
MDVN's Quick Ratio is ranked lower than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. MDVN: 2.38 )
Ranked among companies with meaningful Quick Ratio only.
MDVN' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 3.88 Max: 27.3
Current: 2.38
1.88
27.3
Days Sales Outstanding 151.52
MDVN's Days Sales Outstanding is ranked lower than
83% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. MDVN: 151.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDVN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.21  Med: 98.56 Max: 151.52
Current: 151.52
34.21
151.52

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 130.43
MDVN's Price/Net Current Asset Value is ranked lower than
98% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. MDVN: 130.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDVN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.12  Med: 42.68 Max: 364
Current: 130.43
1.12
364
Price/Tangible Book 46.88
MDVN's Price/Tangible Book is ranked lower than
95% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. MDVN: 46.88 )
Ranked among companies with meaningful Price/Tangible Book only.
MDVN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.37  Med: 7.22 Max: 1281.11
Current: 46.88
0.37
1281.11
Price/Projected FCF 9.22
MDVN's Price/Projected FCF is ranked lower than
72% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. MDVN: 9.22 )
Ranked among companies with meaningful Price/Projected FCF only.
MDVN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.65  Med: 6.00 Max: 34.35
Current: 9.22
1.65
34.35
Price/Median PS Value 0.49
MDVN's Price/Median PS Value is ranked higher than
82% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. MDVN: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
MDVN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.79 Max: 2.78
Current: 0.49
0.23
2.78
Price/Graham Number 9.48
MDVN's Price/Graham Number is ranked lower than
91% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. MDVN: 9.48 )
Ranked among companies with meaningful Price/Graham Number only.
MDVN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.6  Med: 1.71 Max: 10.86
Current: 9.48
0.6
10.86
Earnings Yield (Greenblatt) (%) 4.01
MDVN's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. MDVN: 4.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDVN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 3.20 Max: 8.2
Current: 4.01
0.6
8.2

More Statistics

Revenue(Mil) $943
EPS $ 1.40
Beta1.04
Short Percentage of Float2.53%
52-Week Range $26.41 - 66.40
Shares Outstanding(Mil)164.23

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 933 1,199 1,487
EPS($) 1.35 2.13 2.88
EPS without NRI($) 1.35 2.13 2.88

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:WMD.Germany,
Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
Stocks Fisher Investments Has Bought for Past 2 Quarters May 03 2016 
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Jan 26 2016 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and Medivation Jan 25 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Andreas Halvorsen Buys 2 Million Shares of Medivation Aug 22 2012 
Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, TER Feb 14 2012 

More From Other Websites
Medivation appeals to its 'great teams' of employees in Sanofi saga. But how long can it repel... May 06 2016
2 Longs and 2 Shorts to Watch in the Stock Market May 06 2016
Why These Five Stocks Are Trending Today? May 06 2016
Medivation: Better On Its Own? May 06 2016
Faber Report: Medivation reiterates rejection May 06 2016
Medivation Takeover Talk: Sanofi May Lose Out Despite Offer To Raise Bid May 06 2016
Early movers: CI, ICE, SQ, ATVI, YELP, HON, WYNN, GPRO, HLF & more May 06 2016
Sanofi's Medivation Bear Hug Lacks Muscle May 06 2016
Medivation upgraded by Citigroup May 06 2016
MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 06 2016
Edited Transcript of MDVN earnings conference call or presentation 5-May-16 8:30pm GMT May 06 2016
[$$] Sanofi Says It Will Try to Oust Medivation Board Members if Deal Talks Don’t Start May 05 2016
Sanofi ready to up offer for drugmaker Medivation, could oust board May 05 2016
Sanofi ready to up offer for drugmaker Medivation, could oust board May 05 2016
[$$] Sanofi: Will Try to Oust Medivation Board Unless Deal Talks Start May 05 2016
Medivation Misses Q1 Estimates As Sanofi Turns Up The Buyout Heat May 05 2016
As Sanofi hints at higher takeover price, Medivation holds its ground May 05 2016
Medivation: And Then There Were Five May 05 2016
MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 05 2016
Medivation Inc Earnings Call scheduled for 4:30 pm ET today May 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK